참고문헌
- Ahmad N, Feyes DK, Nieminen AL, et al (1997). Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst, 89, 1881-6. https://doi.org/10.1093/jnci/89.24.1881
- Amaral JD, Xavier JM, Steer CJ, et al (2010). The role of p53 in apoptosis. Discov Med, 9, 145-52.
- Bae SS, Perry DK, Oh YS, et al (2000). Proteolytic cleavage of phospholipase C-gamma1 during apoptosis in Molt-4 cells. FASEB J, 14, 1083-92.
- Binder D, Hegenbarth K (2013). Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol, 7, 221-34.
- Donnerstag B, Ohlenschlager G, Cinatl J, et al (1996). Reduced glutathione and S-acetylglutathione as selective apoptosisinducing agents in cancer therapy. Cancer Lett, 110, 63-70. https://doi.org/10.1016/S0304-3835(96)04461-8
- Emoto Y, Manome Y, Meinhardt G, et al (1995). Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J, 14, 6148-56.
- Feng Z (2010). p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol, 2, 1057. https://doi.org/10.1101/cshperspect.a001057
- Fossella F, Pereira JR, von Pawel J, et al (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol, 21, 3016-24. https://doi.org/10.1200/JCO.2003.12.046
- Fridman JS, Lowe SW (2003). Control of apoptosis by p53. Oncogene, 22, 9030-40. https://doi.org/10.1038/sj.onc.1207116
- Hong H, Park YK, Park JW, et al (2012). BAI, a 3-aminoindazole derivative, inhibits interleukin-1beta-induced expression of cyclooxygenase-2 in A549 human airway cells. Int J Mol Med, 29, 454-60.
- Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
- Kim S, Lee J, Jang BC, et al (2013). BAI, a novel cyclindependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt. J Cell Biochem, 114, 282-93. https://doi.org/10.1002/jcb.24314
- Lee J, Choi H, Kim KH, et al (2008). Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett, 18, 2292-5. https://doi.org/10.1016/j.bmcl.2008.03.002
- Li Q, Ren FQ, Yang CL, et al (2015). Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 16, 3035-42. https://doi.org/10.7314/APJCP.2015.16.7.3035
- Liu CJ, Zhang XL, Luo DY, et al (2015). Exogenous p53 upregulated modulator of apoptosis (PUMA) decreases growth of lung cancer A549 cells. Asian Pac J Cancer Prev, 16, 741-6. https://doi.org/10.7314/APJCP.2015.16.2.741
- Logue SE, Martin SJ (2008). Caspase activation cascades in apoptosis. Biochem Soc Trans, 36, 1-9. https://doi.org/10.1042/BST0360001
- Nakano K, Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 7, 683-94. https://doi.org/10.1016/S1097-2765(01)00214-3
- Oh JH, Park EJ, Park JW, et al (2010). A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells. Int Immunopharmacol, 10, 572-9. https://doi.org/10.1016/j.intimp.2010.02.004
- Rufini A, Tucci P, Celardo I, et al (2013). Senescence and aging: the critical roles of p53. Oncogene, 32, 5129-43. https://doi.org/10.1038/onc.2012.640
- Saika K, Machii R (2012). Cancer mortality attributable to tobacco by region based on the WHO Global Report. Jpn J Clin Oncol, 42, 771-2. https://doi.org/10.1093/jjco/hys117
- Scagliotti GV, De Marinis F, Rinaldi M, et al (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol, 20, 4285-91. https://doi.org/10.1200/JCO.2002.02.068
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Shin HC, Song DW, Baek WK, et al (2009). Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy, 55, 353-62. https://doi.org/10.1159/000232450
- Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
- Sledge GW, Jr. (2005). What is targeted therapy? J Clin Oncol, 23, 1614-5. https://doi.org/10.1200/JCO.2005.01.016
- Wu DM, Zhang P, Xu GC, et al (2015). Pemetrexed induces G1 phase arrest and apoptosis through inhi`biting Akt activation in human non small lung cancer cell line A549. Asian Pac J Cancer Prev, 16, 1507-13. https://doi.org/10.7314/APJCP.2015.16.4.1507
- Xu Y, Zhang Y, Ma S (2011). EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 73, 249-55. https://doi.org/10.1016/j.lungcan.2011.04.017
피인용 문헌
- Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells vol.36, pp.5, 2016, https://doi.org/10.3892/or.2016.5131